{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:01:07Z","timestamp":1794852067572,"version":"4.9.1"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cyclin-dependent kinase 4\/6 inhibitors (CDK4\/6is) in combination with endocrine therapy are the standard treatment for patients with hormone receptor\u2013positive, HER2\u2013negative metastatic breast cancer (mBC). Despite the efficacy of CDK4\/6is, intrinsic resistance occurs in approximately one-third of patients, highlighting the need for reliable predictive biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Single-cell RNA sequencing analyzed metastatic tumors from HR+\/HER2- mBC patients pre-CDK4\/6i treatment at baseline (BL) and\/or at disease progression. BL samples were from CDK4\/6i responders (median progression-free survival [mPFS]\u2009=\u200925.5\u00a0months), while progressors were categorized as early-progressors (EP, mPFS\u2009=\u20093\u00a0months) and late-progressors (LP, mPFS\u2009=\u200911\u00a0months). Metastatic sites included liver, pleural effusions, ascites, and bone. InferCNV distinguished tumor cells, and functional analysis utilized the Molecular Signatures Database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      LP tumors displayed enhanced Myc, EMT, TNF-\u03b1, and inflammatory pathways compared to those EP tumors. Samples from BL and LP responders showed increased tumor-infiltrating CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells and natural killer (NK) cells compared to EP non-responders. Notably, despite a high frequency of CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells in responding tumors, a functional analysis revealed significant upregulation of genes associated with stress and apoptosis in proliferative CD4\n                      <jats:sup>+<\/jats:sup>\n                      and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells in BL tumors compared to in EP and LP tumors. These genes, including\n                      <jats:italic>HSP90<\/jats:italic>\n                      and\n                      <jats:italic>HSPA8<\/jats:italic>\n                      , are linked to resistance to PD1\/PD-L1 immune checkpoint inhibitors. A ligand-receptor analysis showed enhanced interactions associated with inhibitory T-cell proliferation (SPP1-CD44) and suppression of immune activity (MDK-NCL) in LP tumors. Longitudinal biopsies consistently revealed dynamic NK cell expansion and enhanced cytotoxic T cell activity, alongside upregulation of immune activity inhibition, in LP tumors compared to in BL tumors. Notably, the predictive biomarker panel from BL tumor cells was validated in 2 independent cohorts, where it consistently predicted a significant improvement in mPFS duration in signature-high versus -low groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This study underscores the significance of molecular biomarkers in predicting clinical outcomes to CDK4\/6i. Tumor-infiltration CD8\n                      <jats:sup>+<\/jats:sup>\n                      T and NK cells may also serve as baseline predictors. These insights pave the way for optimizing therapeutic strategies based on microenvironment-specific changes, providing a personalized and effective approach for managing HR+\/HER2- mBC and improving patient outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-025-02226-9","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T06:55:41Z","timestamp":1739602541000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Single-cell RNA sequencing identifies molecular biomarkers predicting late progression to CDK4\/6 inhibition in patients with HR+\/HER2-\u00a0metastatic breast cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Linjie","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Mastoraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiayu","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Kettner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshara Singareeka","family":"Raghavendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasish","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthil","family":"Damodaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly K.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khandan","family":"Keyomarsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"key":"2226_CR1","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.\u00a0CA Cancer J Clin.\u00a02021;71(3):209\u201349.","DOI":"10.3322\/caac.21660"},{"key":"2226_CR2","doi-asserted-by":"crossref","unstructured":"Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, Cronin KA. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.\u00a0J Natl Cancer Inst. 2014;106(5):dju055.","DOI":"10.1093\/jnci\/dju055"},{"key":"2226_CR3","doi-asserted-by":"crossref","unstructured":"Reinert T, Barrios CH. Optimal management of hormone receptor positive metastatic breast cancer in 2016.\u00a0Ther Adv Med Oncol. 2015;7(6):304\u201320.","DOI":"10.1177\/1758834015608993"},{"key":"2226_CR4","unstructured":"Network, N. C. C. NCCN Guidelines for Breast Cancer V.1.2023;\u00a02023."},{"issue":"20","key":"2226_CR5","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925\u201336.","journal-title":"N Engl J Med"},{"issue":"20","key":"2226_CR6","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J, Bondarenko I, Im S-A, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926\u201336.","journal-title":"N Engl J Med"},{"issue":"3","key":"2226_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC, Ro J, Andr\u00e9 F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K. Palbociclib in hormone-receptor\u2013positive advanced breast cancer. N Engl J Med. 2015;373(3):209\u201319.","journal-title":"N Engl J Med"},{"issue":"18","key":"2226_CR8","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, Andr\u00e9 F, Winer EP. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738\u201348.","journal-title":"N Engl J Med"},{"issue":"4","key":"2226_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","volume":"381","author":"S-A Im","year":"2019","unstructured":"Im S-A, Lu Y-S, Bardia A, Harbeck N, Colleoni M, Franke F, Chow L, Sohn J, Lee K-S, Campos-Gomez S. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307\u201316.","journal-title":"N Engl J Med"},{"issue":"10","key":"2226_CR10","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Hart L, Campone M, Petrakova K, Winer EP, Janni W. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942\u201350.","journal-title":"N Engl J Med"},{"issue":"1","key":"2226_CR11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge","year":"2020","unstructured":"Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor\u2013positive, ERBB2-negative breast cancer that progressed on endocrine therapy\u2014MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6(1):116\u201324.","journal-title":"JAMA Oncol"},{"issue":"25","key":"2226_CR12","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge Jr","year":"2017","unstructured":"Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875\u201384.","journal-title":"J Clin Oncol"},{"issue":"32","key":"2226_CR13","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Tr\u00e9dan O, Chen S-C, Manso L. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J clin oncol. 2017;35(32):3638\u201346.","journal-title":"J clin oncol"},{"issue":"1","key":"2226_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","volume":"5","author":"S Johnston","year":"2019","unstructured":"Johnston S, Martin M, Di Leo A, Im S-A, Awada A, Forrester T, Frenzel M, Hardebeck MC, Cox J, Barriga S. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ breast cancer. 2019;5(1):5.","journal-title":"NPJ breast cancer"},{"issue":"12","key":"2226_CR15","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1002\/ijc.33959","volume":"150","author":"MJ Ha","year":"2022","unstructured":"Ha MJ, Singareeka Raghavendra A, Kettner NM, Qiao W, Damodaran S, Layman RM, Hunt KK, Shen Y, Tripathy D, Keyomarsi K. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+\/HER2\u2212 metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: a large institutional study. Int J Cancer. 2022;150(12):2025\u201337.","journal-title":"Int J Cancer"},{"key":"2226_CR16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1200\/EDBK_281085","volume":"40","author":"ES Knudsen","year":"2020","unstructured":"Knudsen ES, Shapiro GI, Keyomarsi K. Selective CDK4\/6 inhibitors: biologic outcomes, determinants of sensitivity, mechanisms of resistance, combinatorial approaches, and pharmacodynamic biomarkers. Am Soc Clin Oncol Educ Book. 2020;40:115\u201326.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"2226_CR17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1158\/1078-0432.CCR-19-0751","volume":"26","author":"RS Finn","year":"2020","unstructured":"Finn RS, Liu Y, Zhu Z, Martin M, Rugo HS, Di\u00e9ras V, Im S-A, Gelmon KA, Harbeck N, Lu DR. Biomarker analyses of response to cyclin-dependent kinase 4\/6 inhibition and endocrine therapy in women with treatment-na\u00efve metastatic breast cancer. Clin Cancer Res. 2020;26(1):110\u201321.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2226_CR18","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","volume":"8","author":"B O'Leary","year":"2018","unstructured":"O\u2019Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, Andr\u00e9 F, Loibl S, Loi S, Garcia-Murillas I. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov. 2018;8(11):1390\u2013403.","journal-title":"Cancer Discov"},{"issue":"3","key":"2226_CR19","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/annonc\/mdx784","volume":"29","author":"R Condorelli","year":"2018","unstructured":"Condorelli R, Spring L, O\u2019shaughnessy J, Lacroix L, Bailleux C, Scott V, Dubois J, Nagy RJ, Lanman RB, Iafrate AJ. Polyclonal RB1 mutations and acquired resistance to CDK 4\/6 inhibitors in patients with metastatic breast cancer. Ann Oncol. 2018;29(3):640\u20135.","journal-title":"Ann Oncol"},{"issue":"6","key":"2226_CR20","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","volume":"34","author":"Z Li","year":"2018","unstructured":"Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, Hsieh W, Sanchez-Vega F, Brown DN, Paula AFDC. Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the hippo pathway. Cancer Cell. 2018;34(6):893\u2013905.","journal-title":"Cancer Cell"},{"issue":"13","key":"2226_CR21","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1200\/JCO.20.02977","volume":"39","author":"A Prat","year":"2021","unstructured":"Prat A, Chaudhury A, Solovieff N, Par\u00e9 L, Martinez D, Chic N, Mart\u00ednez-S\u00e1ez O, Bras\u00f3-Maristany F, Lteif A, Taran T. Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA phase III studies. J Clin Oncol. 2021;39(13):1458.","journal-title":"J Clin Oncol"},{"key":"2226_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10549-020-05782-4","volume":"184","author":"RS Finn","year":"2020","unstructured":"Finn RS, Cristofanilli M, Ettl J, Gelmon KA, Colleoni M, Giorgetti C, Gauthier E, Liu Y, Lu DR, Zhang Z. Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. Breast Cancer Res Treat. 2020;184:23\u201335.","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"2226_CR23","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1038\/onc.2016.379","volume":"36","author":"C Yang","year":"2017","unstructured":"Yang C, Li Z, Bhatt T, Dickler M, Giri D, Scaltriti M, Baselga J, Rosen N, Chandarlapaty S. Acquired CDK6 amplification promotes breast cancer resistance to CDK4\/6 inhibitors and loss of ER signaling and dependence. Oncogene. 2017;36(16):2255\u201364.","journal-title":"Oncogene"},{"key":"2226_CR24","doi-asserted-by":"publisher","first-page":"666","DOI":"10.3389\/fonc.2019.00666","volume":"9","author":"A McCartney","year":"2019","unstructured":"McCartney A, Migliaccio I, Bonechi M, Biagioni C, Romagnoli D, De Luca F, Galardi F, Risi E, De Santo I, Benelli M. Mechanisms of resistance to CDK4\/6 inhibitors: potential implications and biomarkers for clinical practice. Front Oncol. 2019;9:666.","journal-title":"Front Oncol"},{"key":"2226_CR25","doi-asserted-by":"crossref","unstructured":"Hortobagyi GN, Paluch-Shimon S, Petrakova K, Villanueva C, Chan A, Nusch A, Yap YS, Hart L, Favret A, Marschner N. First-line ribociclib (RIB)+ letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2\u2013) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses. In: American Society of Clinical Oncology; 2018.","DOI":"10.1200\/JCO.2018.36.15_suppl.1022"},{"issue":"8","key":"2226_CR26","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/2159-8290.CD-19-1390","volume":"10","author":"SA Wander","year":"2020","unstructured":"Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, Kim D, Luo F, Mao P, Helvie K. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor\u2013positive metastatic breast cancer. Cancer Discov. 2020;10(8):1174\u201393.","journal-title":"Cancer Discov"},{"key":"2226_CR27","doi-asserted-by":"crossref","unstructured":"Asghar US, Kanani R, Roylance R, Mittnacht S. Systematic review of molecular biomarkers predictive of resistance to CDK4\/6 inhibition in metastatic breast cancer. JCO Precis Oncol. 2022;6:e2100002.","DOI":"10.1200\/PO.21.00002"},{"key":"2226_CR28","doi-asserted-by":"crossref","unstructured":"Uzhachenko RV, Bharti V, Ouyang Z, Blevins A, Mont S, Saleh N, Lawrence HA, Shen C, Chen S-C, Ayers GD. Metabolic modulation by CDK4\/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors.\u00a0Cell Rep.\u00a02021;35(1).","DOI":"10.1016\/j.celrep.2021.108944"},{"issue":"7668","key":"2226_CR29","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, Khan N, Ubellacker JM, Xie S, Metzger-Filho O. CDK4\/6 inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471\u20135.","journal-title":"Nature"},{"issue":"11","key":"2226_CR30","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1016\/j.celrep.2018.02.053","volume":"22","author":"DA Schaer","year":"2018","unstructured":"Schaer DA, Beckmann RP, Dempsey JA, Huber L, Forest A, Amaladas N, Li Y, Wang YC, Rasmussen ER, Chin D. The CDK4\/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade. Cell Rep. 2018;22(11):2978\u201394.","journal-title":"Cell Rep"},{"issue":"2","key":"2226_CR31","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","volume":"8","author":"J Deng","year":"2018","unstructured":"Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR. CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 2018;8(2):216\u201333.","journal-title":"Cancer Discov"},{"issue":"2","key":"2226_CR32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3390\/genes12020159","volume":"12","author":"K Pandey","year":"2021","unstructured":"Pandey K, Lee E, Park N, Hur J, Cho YB, Katuwal NB, Kim SK, Lee SA, Kim I, An HJ. Deregulated immune pathway associated with palbociclib resistance in preclinical breast cancer models: Integrative genomics and transcriptomics. Genes. 2021;12(2):159.","journal-title":"Genes"},{"issue":"5","key":"2226_CR33","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.3192","volume":"33","author":"R Satija","year":"2015","unstructured":"Satija R, Farrell JA, Gennert D, Schier AF, Regev A. Spatial reconstruction of single-cell gene expression data. Nat Biotechnol. 2015;33(5):495\u2013502.","journal-title":"Nat Biotechnol"},{"key":"2226_CR34","doi-asserted-by":"crossref","unstructured":"McInnes L, Healy J, Melville J. Umap: Uniform manifold approximation and projection for dimension reduction.\u00a02018. arXiv preprint arXiv:1802.03426.\u00a0","DOI":"10.21105\/joss.00861"},{"issue":"6190","key":"2226_CR35","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344(6190):1396\u2013401.","journal-title":"Science"},{"issue":"2","key":"2226_CR36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran D, Looney AP, Liu L, Wu E, Fong V, Hsu A, Chak S, Naikawadi RP, Wolters PJ, Abate AR. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol. 2019;20(2):163\u201372.","journal-title":"Nat Immunol"},{"issue":"9","key":"2226_CR37","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","volume":"53","author":"SZ Wu","year":"2021","unstructured":"Wu SZ, Al-Eryani G, Roden DL, Junankar S, Harvey K, Andersson A, Thennavan A, Wang C, Torpy JR, Bartonicek N. A single-cell and spatially resolved atlas of human breast cancers. Nat Genet. 2021;53(9):1334\u201347.","journal-title":"Nat Genet"},{"issue":"7745","key":"2226_CR38","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41586-019-0969-x","volume":"566","author":"J Cao","year":"2019","unstructured":"Cao J, Spielmann M, Qiu X, Huang X, Ibrahim DM, Hill AJ, Zhang F, Mundlos S, Christiansen L, Steemers FJ. The single-cell transcriptional landscape of mammalian organogenesis. Nature. 2019;566(7745):496\u2013502.","journal-title":"Nature"},{"key":"2226_CR39","doi-asserted-by":"crossref","unstructured":"Korotkevich G, Sukhov V, Budin N, Shpak B, Artyomov MN, Sergushichev A. Fast gene set enrichment analysis. BioRxiv.\u00a02016:060012.","DOI":"10.1101\/060012"},{"key":"2226_CR40","unstructured":"Chu Y, Dai E, Li Y, Han G, Pei G, Ingram DR, Thakkar K, Qin J-J, Dang M, Le X. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance.\u00a0Nat\u00a0Med. 2023:1\u201313."},{"issue":"5","key":"2226_CR41","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.cell.2018.05.060","volume":"174","author":"E Azizi","year":"2018","unstructured":"Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C, Prabhakaran S, Nainys J, Wu K, Kiseliovas V, Setty M. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell. 2018;174(5):1293\u2013308.","journal-title":"Cell"},{"issue":"1","key":"2226_CR42","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41467-022-35238-w","volume":"14","author":"S Tietscher","year":"2023","unstructured":"Tietscher S, Wagner J, Anzeneder T, Langwieder C, Rees M, Sobottka B, de Souza N, Bodenmiller B. A comprehensive single-cell map of T cell exhaustion-associated immune environments in human breast cancer. Nat Commun. 2023;14(1):98.","journal-title":"Nat Commun"},{"key":"2226_CR43","doi-asserted-by":"crossref","unstructured":"Gavish A, Tyler M, Greenwald AC, Hoefflin R, Simkin D, Tschernichovsky R, Galili Darnell N, Somech E, Barbolin C, Antman T. Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours. Nature. 2023;1\u20139.","DOI":"10.1038\/s41586-023-06130-4"},{"issue":"1","key":"2226_CR44","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan C-H, Myung P, Plikus MV, Nie Q. Inference and analysis of cell-cell communication using Cell Chat. Nat Commun. 2021;12(1):1088.","journal-title":"Nat Commun"},{"key":"2226_CR45","unstructured":"Andrews, S. Babraham bioinformatics-FastQC a quality control tool for high throughput sequence data.\u00a02010. URL: https:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/."},{"key":"2226_CR46","doi-asserted-by":"crossref","unstructured":"Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 2011;17(1):10\u20132.","DOI":"10.14806\/ej.17.1.200"},{"key":"2226_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/gb-2013-14-4-r36","volume":"14","author":"D Kim","year":"2013","unstructured":"Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14:1\u201313.","journal-title":"Genome Biol"},{"issue":"7","key":"2226_CR48","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923\u201330.","journal-title":"Bioinformatics"},{"issue":"1","key":"2226_CR49","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139\u201340.","journal-title":"Bioinformatics"},{"key":"2226_CR50","doi-asserted-by":"crossref","unstructured":"Park YH, Im S-A, Park K, Wen J, Lee K-H, Choi Y-L, Lee W-C, Min A, Bonato V, Park S. Longitudinal multi-omics study of palbociclib resistance in HR-positive\/HER2-negative metastatic breast cancer. Genome Med. 2023;15(1):55.","DOI":"10.1186\/s13073-023-01201-7"},{"key":"2226_CR51","doi-asserted-by":"crossref","unstructured":"Ritchie ME, Phipson B, Wu DI, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","DOI":"10.1093\/nar\/gkv007"},{"key":"2226_CR52","volume-title":"Data analysis","author":"H Wickham","year":"2016","unstructured":"Wickham H, Wickham H. Data analysis. Springer; 2016."},{"key":"2226_CR53","volume-title":"inferCNV of the Trinity CTAT Project","author":"T Tickle","year":"2019","unstructured":"Tickle T, Tirosh I, Georgescu C, Brown M, Haas B. inferCNV of the Trinity CTAT Project. Broad Institute of MIT and Harvard: Klarman Cell Observatory; 2019."},{"issue":"12","key":"2226_CR54","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, Baglaenko Y, Brenner M, Loh P-R, Raychaudhuri S. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods. 2019;16(12):1289\u201396.","journal-title":"Nat Methods"},{"key":"2226_CR55","doi-asserted-by":"crossref","unstructured":"Bowley TY, Lagutina IV, Francis C, Sivakumar S, Selwyn RG, Taylor E, Guo Y, Fahy BN, Tawfik B, Marchetti D. The RPL\/RPS gene signature of melanoma CTCs associates with brain metastasis.\u00a0Cancer Res\u00a0Commun. 2022;2(11):1436\u201348.","DOI":"10.1158\/2767-9764.CRC-22-0337"},{"key":"2226_CR56","doi-asserted-by":"crossref","unstructured":"Scirocchi F, Scagnoli S, Botticelli A, Di Filippo A, Napoletano C, Zizzari IG, Strigari L, Tomao S, Cortesi E, Rughetti A. Immune effects of CDK4\/6 inhibitors in patients with HR+\/HER2\u2212 metastatic breast cancer: relief from immunosuppression is associated with clinical response. EBioMedicine. 2022;79.","DOI":"10.1016\/j.ebiom.2022.104010"},{"issue":"9","key":"2226_CR57","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.1007\/s00432-022-04498-w","volume":"149","author":"M Cheng","year":"2023","unstructured":"Cheng M, Liang G, Yin Z, Lin X, Sun Q, Liu Y. Immunosuppressive role of SPP1-CD44 in the tumor microenvironment of intrahepatic cholangiocarcinoma assessed by single-cell RNA sequencing. J Cancer Res Clin Oncol. 2023;149(9):5497\u2013512.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2226_CR58","doi-asserted-by":"crossref","unstructured":"He C, Sheng L, Pan D, Jiang S, Ding L, Ma X, Liu Y, Jia D. Single-cell transcriptomic analysis revealed a critical role of SPP1\/CD44-mediated crosstalk between macrophages and cancer cells in glioma.\u00a0Front\u00a0Cell Dev\u00a0Biol. 2021;9:779319.","DOI":"10.3389\/fcell.2021.779319"},{"issue":"1","key":"2226_CR59","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3390\/cancers15010164","volume":"15","author":"W Xie","year":"2022","unstructured":"Xie W, Cheng J, Hong Z, Cai W, Zhuo H, Hou J, Lin L, Wei X, Wang K, Chen X. Multi-transcriptomic analysis reveals the heterogeneity and tumor-promoting role of SPP1\/CD44-mediated intratumoral crosstalk in gastric cancer. Cancers. 2022;15(1):164.","journal-title":"Cancers"},{"issue":"1","key":"2226_CR60","doi-asserted-by":"publisher","first-page":"9657","DOI":"10.1038\/s41598-023-33915-4","volume":"13","author":"S Liu","year":"2023","unstructured":"Liu S, Liu Z, Shang A, Xun J, Lv Z, Zhou S, Liu C, Zhang Q, Yang Y. CD44 is a potential immunotherapeutic target and affects macrophage infiltration leading to poor prognosis. Sci Rep. 2023;13(1):9657.","journal-title":"Sci Rep"},{"issue":"6","key":"2226_CR61","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1053\/j.gastro.2021.08.023","volume":"161","author":"P Nallasamy","year":"2021","unstructured":"Nallasamy P, Nimmakayala RK, Karmakar S, Leon F, Seshacharyulu P, Lakshmanan I, Rachagani S, Mallya K, Zhang C, Ly QP. Pancreatic tumor microenvironment factor promotes cancer stemness via SPP1\u2013CD44 Axis. Gastroenterology. 2021;161(6):1998\u20132013.","journal-title":"Gastroenterology"},{"key":"2226_CR62","doi-asserted-by":"publisher","first-page":"1145300","DOI":"10.3389\/fimmu.2023.1145300","volume":"14","author":"X Yu","year":"2023","unstructured":"Yu X, Xie L, Ge J, Li H, Zhong S, Liu X. Integrating single-cell RNA-seq and spatial transcriptomics reveals MDK-NCL dependent immunosuppressive environment in endometrial carcinoma. Front Immunol. 2023;14:1145300.","journal-title":"Front Immunol"},{"issue":"2","key":"2226_CR63","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.immuni.2014.06.011","volume":"41","author":"C Wu","year":"2014","unstructured":"Wu C, Thalhamer T, Franca RF, Xiao S, Wang C, Hotta C, Zhu C, Hirashima M, Anderson AC, Kuchroo VK. Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells. Immunity. 2014;41(2):270\u201382.","journal-title":"Immunity"},{"issue":"4","key":"2226_CR64","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.immuni.2013.08.029","volume":"39","author":"Y Kumamoto","year":"2013","unstructured":"Kumamoto Y, Linehan M, Weinstein JS, Laidlaw BJ, Craft JE, Iwasaki A. CD301b+ dermal dendritic cells drive T helper 2 cell-mediated immunity. Immunity. 2013;39(4):733\u201343.","journal-title":"Immunity"},{"issue":"1","key":"2226_CR65","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","volume":"6","author":"Z Duan","year":"2021","unstructured":"Duan Z, Luo Y. Targeting macrophages in cancer immunotherapy. Signal Transduct Target Ther. 2021;6(1):127.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"2226_CR66","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41401-020-0416-4","volume":"42","author":"X-Q Xu","year":"2021","unstructured":"Xu X-Q, Pan X-H, Wang T-T, Wang J, Yang B, He Q-J, Ding L. Intrinsic and acquired resistance to CDK4\/6 inhibitors and potential overcoming strategies. Acta Pharmacol Sin. 2021;42(2):171\u20138.","journal-title":"Acta Pharmacol Sin"},{"issue":"8","key":"2226_CR67","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","volume":"76","author":"MT Herrera-Abreu","year":"2016","unstructured":"Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, Pearson A, Guzman M, Rodriguez O, Grueso J. Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor\u2013positive breast cancer. Can Res. 2016;76(8):2301\u201313.","journal-title":"Can Res"},{"issue":"1","key":"2226_CR68","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12943-022-01642-5","volume":"21","author":"H Mo","year":"2022","unstructured":"Mo H, Liu X, Xue Y, Chen H, Guo S, Li Z, Wang S, Li C, Han J, Fu M. S6K1 amplification confers innate resistance to CDK4\/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer. Mol Cancer. 2022;21(1):171.","journal-title":"Mol Cancer"},{"issue":"10","key":"2226_CR69","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.ccell.2021.08.009","volume":"39","author":"K Freeman-Cook","year":"2021","unstructured":"Freeman-Cook K, Hoffman RL, Miller N, Almaden J, Chionis J, Zhang Q, Eisele K, Liu C, Zhang C, Huser N. Expanding control of the tumor cell cycle with a CDK2\/4\/6 inhibitor. Cancer Cell. 2021;39(10):1404\u201321.","journal-title":"Cancer Cell"},{"issue":"10","key":"2226_CR70","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1158\/1535-7163.MCT-12-0562","volume":"11","author":"F Liu","year":"2012","unstructured":"Liu F, Korc M. Cdk4\/6 inhibition induces epithelial\u2013mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther. 2012;11(10):2138\u201348.","journal-title":"Mol Cancer Ther"},{"issue":"17","key":"2226_CR71","doi-asserted-by":"publisher","first-page":"4870","DOI":"10.1158\/1078-0432.CCR-19-4191","volume":"27","author":"C De Angelis","year":"2021","unstructured":"De Angelis C, Fu X, Cataldo ML, Nardone A, Pereira R, Veeraraghavan J, Nanda S, Qin L, Sethunath V, Wang T. Activation of the IFN signaling pathway is associated with resistance to CDK4\/6 inhibitors and immune checkpoint activation in ER-positive breast cancer. Clin Cancer Res. 2021;27(17):4870\u201382.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2226_CR72","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE De Visser","year":"2023","unstructured":"De Visser KE, Joyce JA. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374\u2013403.","journal-title":"Cancer Cell"},{"key":"2226_CR73","doi-asserted-by":"crossref","unstructured":"El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, De Freitas JR, Sur D, Amendola LC, Gharib M. The tale of TILs in breast cancer: a report from the international immuno-oncology biomarker working group. NPJ Breast Cancer. 2021;7(1):150.","DOI":"10.1038\/s41523-021-00346-1"},{"issue":"1","key":"2226_CR74","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40\u201350.","journal-title":"Lancet Oncol"},{"issue":"7","key":"2226_CR75","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","volume":"31","author":"S Loi","year":"2013","unstructured":"Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02\u201398. J Clin Oncol. 2013;31(7):860\u20137.","journal-title":"J Clin Oncol"},{"issue":"7686","key":"2226_CR76","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature25015","volume":"553","author":"J Zhang","year":"2018","unstructured":"Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, Tan Y, Ci Y, Wu F, Dai X. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3\u2013SPOP to control cancer immune surveillance. Nature. 2018;553(7686):91\u20135.","journal-title":"Nature"},{"key":"2226_CR77","doi-asserted-by":"crossref","unstructured":"Mayer EL, Ren Y, Wagle N, Ma C, DeMichele A, Cristofanilli M, Meisel J. Palbociclib after CDK4\/6i and endocrine therapy (PACE): a randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+\/HER2-metastatic breast cancer;\u00a02022.","DOI":"10.1158\/1538-7445.SABCS22-GS3-06"},{"key":"2226_CR78","doi-asserted-by":"crossref","unstructured":"Rugo HS, Kabos P, Beck JT, Jerusalem G, Wildiers H, Sevillano E, Paz-Ares L, Chisamore MJ, Chapman SC, Hossain AM. Abemaciclib in combination with pembrolizumab for HR+, HER2\u2212 metastatic breast cancer: Phase 1b study. NPJ Breast Cancer. 2022;8(1):118.","DOI":"10.1038\/s41523-022-00482-2"},{"key":"2226_CR79","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2021.05.035","volume":"154","author":"Y Yuan","year":"2021","unstructured":"Yuan Y, Lee JS, Yost SE, Frankel PH, Ruel C, Egelston CA, Guo W, Padam S, Tang A, Martinez N. Phase I\/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer. Eur J Cancer. 2021;154:11\u201320.","journal-title":"Eur J Cancer"},{"key":"2226_CR80","doi-asserted-by":"crossref","unstructured":"Herold CI, Trippa L, Li T, Do K, Bardia A, Anderson L, Montazeri K, Pittenger J, Andrews C, Mittendorf EA. Abstract P3\u201314\u201303: a phase 1B study of the CDK4\/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive metastatic breast cancer (HR+ MBC) and metastatic ovarian cancer (MOC).\u00a0Cancer Res. 2020;80(4_Supplement):P3\u201314.","DOI":"10.1158\/1538-7445.SABCS19-P3-14-03"},{"issue":"1","key":"2226_CR81","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, Li Y, Tan J, Xu L, Li Y. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16(1):101.","journal-title":"J Hematol Oncol"},{"key":"2226_CR82","doi-asserted-by":"crossref","unstructured":"Cortese N, Carriero R, Laghi L, Mantovani A, Marchesi F. Prognostic significance of tumor-associated macrophages: Past, present and future;\u00a02020.","DOI":"10.1016\/j.smim.2020.101408"},{"issue":"6","key":"2226_CR83","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19(6):369\u201382.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2226_CR84","doi-asserted-by":"publisher","first-page":"14333","DOI":"10.1038\/s41598-020-70353-y","volume":"10","author":"C Lantz","year":"2020","unstructured":"Lantz C, Radmanesh B, Liu E, Thorp EB, Lin J. Single-cell RNA sequencing uncovers heterogenous transcriptional signatures in macrophages during efferocytosis. Sci Rep. 2020;10(1):14333.","journal-title":"Sci Rep"},{"key":"2226_CR85","doi-asserted-by":"crossref","unstructured":"Mehta AK, Kadel S, Townsend MG, Oliwa M, Guerriero JL. Macrophage biology and mechanisms of immune suppression in breast cancer. Front Immunol. 2021;12:643771.","DOI":"10.3389\/fimmu.2021.643771"},{"key":"2226_CR86","doi-asserted-by":"crossref","unstructured":"Mehta AK, Cheney EM, Hartl CA, Pantelidou C, Oliwa M, Castrillon JA, Lin J-R, Hurst KE, de Oliveira Taveira M, Johnson NT. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer.\u00a0Nat\u00a0Cancer. 2021;2(1):66\u201382.","DOI":"10.1038\/s43018-020-00148-7"},{"issue":"5","key":"2226_CR87","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.molmed.2018.03.006","volume":"24","author":"JL Guerriero","year":"2018","unstructured":"Guerriero JL. Macrophages: the road less traveled, changing anticancer therapy. Trends Mol Med. 2018;24(5):472\u201389.","journal-title":"Trends Mol Med"},{"issue":"7645","key":"2226_CR88","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nature21409","volume":"543","author":"JL Guerriero","year":"2017","unstructured":"Guerriero JL, Sotayo A, Ponichtera HE, Castrillon JA, Pourzia AL, Schad S, Johnson SF, Carrasco RD, Lazo S, Bronson RT. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature. 2017;543(7645):428\u201332.","journal-title":"Nature"},{"issue":"1","key":"2226_CR89","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s40164-024-00571-x","volume":"13","author":"S-Z Xie","year":"2024","unstructured":"Xie S-Z, Yang L-Y, Wei R, Shen X-T, Pan J-J, Yu S-Z, Zhang C, Xu H, Xu J-F, Zheng X. Targeting SPP1-orchestrated neutrophil extracellular traps-dominant pre-metastatic niche reduced HCC lung metastasis. Exp Hematol Oncol. 2024;13(1):111.","journal-title":"Exp Hematol Oncol"},{"key":"2226_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-021-02212-3","volume":"21","author":"B Hu","year":"2021","unstructured":"Hu B, Qin C, Li L, Wei L, Mo X, Fan H, Lei Y, Wei F, Zou D. Midkine promotes glioblastoma progression via PI3K-Akt signaling. Cancer Cell Int. 2021;21:1\u201313.","journal-title":"Cancer Cell Int"},{"key":"2226_CR91","doi-asserted-by":"crossref","unstructured":"Luo L, Wang Y, Mastoraki S, Raghavendra AS, Navarro-Yepes J, Kettner NM, Kim S, Tripathy D, Hunt K, Keyomarsi K. TFF1 and TFF3 predict response to CDK4\/6 inhibitors in breast cancer patients. Cancer Res. 2023;83(7_Supplement):4346.","DOI":"10.1158\/1538-7445.AM2023-4346"},{"key":"2226_CR92","doi-asserted-by":"crossref","unstructured":"Zhang Y, Liu Y, Wang L, Song H. The expression and role of trefoil factors in human tumors.\u00a0Transl\u00a0Cancer Res. 2019;8(4):1609.","DOI":"10.21037\/tcr.2019.07.48"},{"issue":"1","key":"2226_CR93","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.1038\/s41598-017-05129-y","volume":"7","author":"Y Ishibashi","year":"2017","unstructured":"Ishibashi Y, Ohtsu H, Ikemura M, Kikuchi Y, Niwa T, Nishioka K, Uchida Y, Miura H, Aikou S, Gunji T. Serum TFF1 and TFF3 but not TFF2 are higher in women with breast cancer than in women without breast cancer. Sci Rep. 2017;7(1):4846.","journal-title":"Sci Rep"},{"issue":"3","key":"2226_CR94","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1053\/j.gastro.2011.05.040","volume":"141","author":"S Aikou","year":"2011","unstructured":"Aikou S, Ohmoto Y, Gunji T, Matsuhashi N, Ohtsu H, Miura H, Kubota K, Yamagata Y, Seto Y, Nakajima A. Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening. Gastroenterology. 2011;141(3):837\u201345.","journal-title":"Gastroenterology"},{"issue":"3","key":"2226_CR95","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1158\/1078-0432.CCR-05-1545","volume":"12","author":"EM Vestergaard","year":"2006","unstructured":"Vestergaard EM, Borre M, Poulsen SS, Nex\u00f8 E, T\u00f8rring N. Plasma levels of trefoil factors are increased in patients with advanced prostate cancer. Clin Cancer Res. 2006;12(3):807\u201312.","journal-title":"Clin Cancer Res"},{"key":"2226_CR96","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ebiom.2019.03.056","volume":"42","author":"R Jahan","year":"2019","unstructured":"Jahan R, Ganguly K, Smith LM, Atri P, Carmicheal J, Sheinin Y, Rachagani S, Natarajan G, Brand RE, Macha MA. Trefoil factor (s) and CA19. 9: a promising panel for early detection of pancreatic cancer. EBioMedicine. 2019;42:375\u201385.","journal-title":"EBioMedicine"},{"issue":"4","key":"2226_CR97","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3892\/or.2012.1627","volume":"27","author":"Y Qu","year":"2012","unstructured":"Qu Y, Yang Y, Ma D, Xiao W. Increased trefoil factor 3 levels in the serum of patients with three major histological subtypes of lung cancer. Oncol Rep. 2012;27(4):1277\u201383.","journal-title":"Oncol Rep"},{"key":"2226_CR98","doi-asserted-by":"crossref","unstructured":"Muenphon K, Limpaiboon T, Jearanaikoon P, Pairojkul C, Sripa B, Bhudhisawasdi V. Amplification of chromosome 21q22. 3 harboring trefoil factor family genes in liver fluke related cholangiocarcinoma is associated with poor prognosis.\u00a0World J Gastroenterol: WJG. 2006;12(26):4143.","DOI":"10.3748\/wjg.v12.i26.4143"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02226-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02226-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02226-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T06:56:02Z","timestamp":1739602562000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02226-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2226"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02226-9","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,15]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tumor biopsy samples were collected from patients with HR+\/HER2- mBC treated at the University of Texas MD Anderson Cancer Center under the Institutional Review Board (IRB)-approved protocol (PA19-0047). All participants signed informed consent. Clinical data were sourced from electronic medical records (OneConnect and Care Everywhere) and a prospectively maintained Breast Cancer Management System, managed by the Breast Medical Oncology Department from the University of Texas MD Anderson Cancer Center.The validation cohort comprised published sequencing data from Korean patients with HR+\/HER2- mBC (NCT03401359) [\n                      \n                      ]. This cohort included patients with recurrent and\/or mBC treated with palbociclib plus endocrine therapy at Samsung Medical Center and Seoul National University Hospital from 2017 to 2020. All participants signed informed consent. Patients who refused to provide informed consent or withdrew from the study were excluded.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"K.K.: Apeiron, Blueprint Medicines, REPARE, Schrodinger, and Novartis.\u00a0K.K.H.: Armada Health, AstraZeneca, Cairn Surgical, Eli Lilly & Co, Lumicell.\u00a0S.D.: EMD Serono, Guardant Health, Novartis, Pfizer, Sermonix, Taiho. D.T.: AstraZeneca, GlaxoSmithKline, Gilead, Novartis, OncoPep, Pfizer, Polyphor, Personalis, Puma Biotechnology, Sermonix, Stemline-Menarini. The rest of the authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}